Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the ...

Hyperfine Inc. ( (HYPR)) has released its Q3 earnings. Here is a breakdown of the information Hyperfine Inc. presented to its investors. Hyperfine, Inc. is a pioneering health technology company that ...

GUILFORD, Conn., November 19, 2024--Hyperfine, Inc. announces ten scientific abstracts highlighting ultra-low-field imaging will be presented at the RSNA 2024 Annual Meeting. Hyperfine ( NASDAQ ...

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared ...

Today’s presentation at CTAD, a leading international Alzheimer's conference, expands research supporting the value of ultra-low-field MRI in monitoring amyloid-related imaging abnormalities (ARIA).

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared ...

CE approval of the latest generation Swoop® system software is a significant milestone in Hyperfine’s international strategy, allowing broader European commercial expansion. Hyperfine secured ...

Good afternoon. And welcome to Hyperfine's Third Quarter 2024 Earnings Conference Call. Currently, all participants are in listen only mode. We will be facilitating a question-and-answer session ...

Hyperfine (HYPR) announced CE approval of its latest generation of AI-powered Swoop system software under the European Medical Device Regulation. This approval marks a step in positioning ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...